Investor Presentaiton

24 IDE397 Clinical Data Summary - Monotherapy Dose Escalation Cohorts ctDNA Molecular Response demonstrates Tumor Pharmacodynamic Modulation Molecular Response Waterfall (Baseline to C2D1) 586 135 97 100 90 76 = Cohort 5 and 6 Dose 80 70 = Cohort 1 to 4 Dose 60 50 40 30 20 11 8 10 1 0 -10 -20 -13 -14 -30 -40 -50 -60 -70 -51 -58 -67 -80 -90 -100 -100 Dose Cohort 3 Tumor Type Parotid Cohort 3 Pancreatic Cohort 5 Cohort 1 Sarcoma Pancreatic Cohort 4 Pancreatic Cohort 2 Thymic Cohort 4 Cohort 4 Cohort 1 Pancreatic Melanoma Pancreatic Cohort 5 NSCLC Cohort 2 Cohort 6 Cohort 5 NSCLC Bladder Pancreatic IDEAYA Data: Guardant OMNITM ctDNA Molecular Response (n=13 evaluable IDE397 Phase 1 dose escalation samples) Molecular Response ctDNA Molecular Response: IDE397 Dose-Dependent Tumor Pharmacodynamic Modulation 100% (2 of 2) Molecular Responders in NSCLC 75% (3 of 4) Molecular Responders in Cohort 5 and Cohort 6 Patients 31% (4 of 13) Molecular Responders across all dose- escalation Cohorts 1 to 6 IDEAVA BIOSCIENCES

View entire presentation